Skip to main content
No. of Recommendations: 1
Ions may not have the homerun, but IONS is of a different sort. It’s pipeline is so loaded that it can continue to do what it does and continue to grow earnings. That is what a more mature biotech does, but that is what IONS is doing. If it creates shareholder value, more power to it.


I prefer a biotech, or any business at that matter, that can focus on a few, or even one thing, and do it better than anyone else. For IONS that means picking a few drugs and bring them wholly owned or 50% owned at least, to market, instead of brining 30 drugs to clinical and getting a small cut of each.

Different investing scenarios. My preference is the latter, if the former works for shareholders than so be it.

Tinker
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.